Literature DB >> 22829013

Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype.

Miguel A M Moreira1, Irina G Bobrovnitchaia, Maria Angélica F D Lima, Anna Cláudia E Santos, Jesus P Ramos, Kelly R L Souza, Ana Peixoto, Manuel R Teixeira, Fernando R Vargas.   

Abstract

We have screened BRCA2 c.156_157insAlu founder mutation in a cohort of 168 women with diagnosis of breast cancer referred for genetic counseling because of risk of being carriers of hereditary breast and ovarian cancer syndrome. Portuguese founder mutation BRCA2 c.156_157insAlu was identified in three unrelated breast cancer probands. Genotyping identified a common haplotype between markers D13S260 and D13S171, and allele sizes were compatible to those described in the Portuguese families. Allele sizes of marker D13S1246, however, were concordant in two families, suggesting that the haplotype may be larger in a subset of families. Tumor phenotypes in Brazilian families seem to reinforce the high prevalence of breast cancer among affected males. However, an apparent excess of gastrointestinal and tongue neoplasias were also observed in these families. Although these tumors are not part of the phenotypic spectrum of hereditary breast and ovarian cancer syndrome, they might be accounted for by other risk alleles contained in the founder haplotype region.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22829013     DOI: 10.1007/s10689-012-9551-5

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  9 in total

1.  International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation.

Authors:  Ana Peixoto; Catarina Santos; Manuela Pinheiro; Pedro Pinto; Maria José Soares; Patrícia Rocha; Leonor Gusmão; António Amorim; Annemarie van der Hout; Anne-Marie Gerdes; Mads Thomassen; Torben A Kruse; Dorthe Cruger; Lone Sunde; Yves-Jean Bignon; Nancy Uhrhammer; Lucie Cornil; Etienne Rouleau; Rosette Lidereau; Drakoulis Yannoukakos; Maroulio Pertesi; Steven Narod; Robert Royer; Maurício M Costa; Conxi Lazaro; Lidia Feliubadaló; Begoña Graña; Ignacio Blanco; Miguel de la Hoya; Trinidad Caldés; Philippe Maillet; Gaelle Benais-Pont; Bruno Pardo; Yael Laitman; Eitan Friedman; Eladio A Velasco; Mercedes Durán; Maria-Dolores Miramar; Ana Rodriguez Valle; María-Teresa Calvo; Ana Vega; Ana Blanco; Orland Diez; Sara Gutiérrez-Enríquez; Judith Balmaña; Teresa Ramon y Cajal; Carmen Alonso; Montserrat Baiget; William Foulkes; Marc Tischkowitz; Rachel Kyle; Nelly Sabbaghian; Patricia Ashton-Prolla; Ingrid P Ewald; Thangarajan Rajkumar; Luisa Mota-Vieira; Giuseppe Giannini; Alberto Gulino; Maria I Achatz; Dirce M Carraro; Brigitte Bressac de Paillerets; Audrey Remenieras; Cindy Benson; Silvia Casadei; Mary-Claire King; Erik Teugels; Manuel R Teixeira
Journal:  Breast Cancer Res Treat       Date:  2010-07-22       Impact factor: 4.872

2.  De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes.

Authors:  Erik Teugels; Sylvia De Brakeleer; Guido Goelen; Willy Lissens; Erica Sermijn; Jacques De Grève
Journal:  Hum Mutat       Date:  2005-09       Impact factor: 4.878

Review 3.  Hereditary breast cancer: clinical features and risk reduction strategies.

Authors:  A Paradiso; S Formenti
Journal:  Ann Oncol       Date:  2011-01       Impact factor: 32.976

4.  Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu.

Authors:  Ana Peixoto; Catarina Santos; Patrícia Rocha; Pedro Pinto; Susana Bizarro; Manuel R Teixeira
Journal:  Breast Cancer Res Treat       Date:  2008-10-14       Impact factor: 4.872

5.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

Authors:  Donald A Berry; Edwin S Iversen; Daniel F Gudbjartsson; Elaine H Hiller; Judy E Garber; Beth N Peshkin; Caryn Lerman; Patrice Watson; Henry T Lynch; Susan G Hilsenbeck; Wendy S Rubinstein; Kevin S Hughes; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

6.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Authors:  G Parmigiani; D Berry; O Aguilar
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

Review 7.  Founder mutations in BRCA1 and BRCA2 genes.

Authors:  R Ferla; V Calò; S Cascio; G Rinaldi; G Badalamenti; I Carreca; E Surmacz; G Colucci; V Bazan; A Russo
Journal:  Ann Oncol       Date:  2007-06       Impact factor: 32.976

8.  The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.

Authors:  Ana Peixoto; Catarina Santos; Patrícia Rocha; Manuela Pinheiro; Sofia Príncipe; Deolinda Pereira; Helena Rodrigues; Fernando Castro; Joaquim Abreu; Leonor Gusmão; António Amorim; Manuel R Teixeira
Journal:  Breast Cancer Res Treat       Date:  2008-03-25       Impact factor: 4.872

9.  Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.

Authors:  Patrícia M Machado; Rita D Brandão; Branca M Cavaco; Joana Eugénio; Sandra Bento; Mónica Nave; Paula Rodrigues; Aires Fernandes; Fátima Vaz
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

  9 in total
  7 in total

Review 1.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

2.  Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.

Authors:  Patricia Ashton-Prolla; Fernando Regla Vargas
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

3.  Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population.

Authors:  Gabriela Es Felix; Camila Abe-Sandes; Taísa Mb Machado-Lopes; Thaís F Bomfim; Rodrigo Santa Cruz Guindalini; Vanessa Catarine Sar Santos; Lorena Meyer; Polyanna C Oliveira; João Cláudio Neiva; Roberto Meyer; Maura Romeo; Maria Betânia Toralles; Ivana Nascimento; Kiyoko Abe-Sandes
Journal:  Hum Genome Var       Date:  2014-10-16

4.  Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.

Authors:  Pedro Pinto; Ana Peixoto; Catarina Santos; Patrícia Rocha; Carla Pinto; Manuela Pinheiro; Luís Leça; Ana Teresa Martins; Verónica Ferreira; Carla Bartosch; Manuel R Teixeira
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

5.  Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.

Authors:  Oubaida ElBiad; Abdelilah Laraqui; Fatima El Boukhrissi; Chaimaa Mounjid; Maryame Lamsisi; Tahar Bajjou; Hicham Elannaz; Amine Idriss Lahlou; Jaouad Kouach; Khadija Benchekroune; Mohammed Oukabli; Hafsa Chahdi; Moulay Mustapha Ennaji; Rachid Tanz; Yassir Sbitti; Mohammed Ichou; Khalid Ennibi; Bouabid Badaoui; Yassine Sekhsokh
Journal:  BMC Cancer       Date:  2022-02-25       Impact factor: 4.430

6.  Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil.

Authors:  Edenir Inêz Palmero; Bárbara Alemar; Lavínia Schüler-Faccini; Pierre Hainaut; Carlos Alberto Moreira-Filho; Ingrid Petroni Ewald; Patricia Koehler Dos Santos; Patricia Lisbôa Izetti Ribeiro; Cristina Brinkmann de Netto Oliveira; Florence Le Calvez-Kelm; Sean Tavtigian; Silvia Liliana Cossio; Roberto Giugliani; Maira Caleffi; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2016-05-24       Impact factor: 1.771

7.  The germline mutational landscape of BRCA1 and BRCA2 in Brazil.

Authors:  Edenir Inêz Palmero; Dirce Maria Carraro; Barbara Alemar; Miguel Angelo Martins Moreira; Ândrea Ribeiro-Dos-Santos; Kiyoko Abe-Sandes; Henrique Campos Reis Galvão; Rui Manuel Reis; Cristiano de Pádua Souza; Natalia Campacci; Maria Isabel Achatz; Rafael Canfield Brianese; Maria Nirvana da Cruz Formiga; Fabiana Baroni Makdissi; Fernando Regla Vargas; Anna Cláudia Evangelista Dos Santos; Hector N Seuanez; Kelly Rose Lobo de Souza; Cristina B O Netto; Patrícia Santos-Silva; Gustavo Stumpf da Silva; Rommel M R Burbano; Sidney Santos; Paulo Pimentel Assumpção; Izabel Maria Monteiro Bernardes; Taisa Manuela Bonfim Machado-Lopes; Thais Ferreira Bomfim; Maria Betânia Pereira Toralles; Ivana Nascimento; Bernardo Garicochea; Sergio D Simon; Simone Noronha; Fernanda Teresa de Lima; Anisse Marques Chami; Camila Matzenbacher Bittar; Jose Bines; Osvaldo Artigalas; Maria Del Pilar Esteves-Diz; Tirzah Braz Petta Lajus; Ana Carolina Leite Vieira Costa Gifoni; Rodrigo S C Guindalini; Terezinha Sarquis Cintra; Ida V D Schwartz; Pricila Bernardi; Diego Miguel; Sonia Tereza Dos Santos Nogueira; Josef Herzog; Jeffrey N Weitzel; Patricia Ashton-Prolla
Journal:  Sci Rep       Date:  2018-06-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.